REGENXBIO Inc., a clinical-stage biotechnology exploring the curative potential of gene therapy based on its NAV Technology Platform, will receive an $80 million milestone payment from Novartis AG based on the achievement of $1.0 billion in cumulative net sales of Zolgensma. Zolgensma uses REGENXBIO’s NAV AAV9 vector and was designed and developed by AveXis, Inc., known as Novartis Gene Therapies. In May 2019, Zolgensma was granted U.S. FDA approval for the treatment of spinal muscular...